Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
Labetalol vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Bupivacaine blocks sodium ion channels on the neuronal membrane, inhibiting depolarization and conduction of nerve impulses. Epinephrine causes local vasoconstriction, delaying absorption and prolonging anesthetic effect.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Local infiltration: up to 30 mL of 0.25% (75 mg) or 0.5% (150 mg) solution. Epidural (lumbar): 10-20 mL of 0.5% (50-100 mg) with 1:200,000 epinephrine, repeated every 1.5-3 hours as needed. Maximum single dose: 225 mg (with epinephrine 1:200,000).
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Terminal half-life of bupivacaine is 2.7–4.2 hours in adults; prolonged to 8–12 hours in neonates and patients with hepatic impairment.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Primarily hepatic metabolism via CYP3A4 and amide hydrolysis; <5% excreted unchanged in urine. Biliary excretion accounts for <2% of total elimination.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist